EPCAM and breast carcinoma: To evaluate the targeted transduction capability of AAV2MEC1 in vivo on EpCAM-positive breast cancer cells 4T-1, we subcutaneously injected 2.5 × 10^5 4T-1 cells into the back of each BALB/c female mice.